Open Beta
MetriLume

US marketsDNTH

SEC-sourced researchBeta

DNTH

Dianthus Therapeutics, Inc. /DE/

Company comparison ↗

Data passport

CIK
0001690585
Exchange
Nasdaq
Business activity
— · SIC 2834
Financial inputs
6/6
Filing date
Sep 18, 2026
SEC registry record
Operating company

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table. Exact amounts and source periods: December 2024: 6,235,000.0000 USD; December 2025: 2,036,000.0000 USD6.2M USD0 USD0December 2024December 2025
DNTH · Exact amounts and source periods · USD
Period endRevenueFiling date
December 20246,235,000.0000Mar 9, 2026
December 20252,036,000.0000Mar 9, 2026

Annual periods · USD

Period endRevenueNet incomeOperating cash flowTotal assetsTotal liabilitiesFiling date
December 20252,036,000.0000-162,337,000.0000-129,060,000.0000530,922,000.000037,521,000.0000Mar 9, 2026
December 20246,235,000.0000-84,969,000.0000-78,180,000.0000374,008,000.000021,531,000.0000Mar 9, 2026

Financial inputs behind the calculation

Financial inputsUSDPeriod endFiling dateForm
RevenueRevenueFromContractWithCustomerExcludingAssessedTax$2.04MDecember 2025Mar 9, 202610-K
Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax$6.24MDecember 2024Mar 9, 202610-K
Net incomeNetIncomeLoss-$162.34MDecember 2025Mar 9, 202610-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities-$129.06MDecember 2025Mar 9, 202610-K
Total assetsAssets$530.92MDecember 2025Mar 9, 202610-K
Total liabilitiesLiabilities$37.52MDecember 2025Mar 9, 202610-K

New filings

Explore methodology ↗